Bayer Enters CAR-T Space With Atara Pact

Pays $60m Upfront

Marianne De Backer, head of pharma BD and licensing at the German firm, told Scrip, "We strongly believe that the future is allogeneic and we were looking for pioneers in the field."

Bayer Pharma AG, Administration and laboratory buildings of Bayer HealthCare Pharmaceuticals in Berlin-Wedding on June 14, 2017, Germany - Image
Bayer building a strong presence in cell and gene therapy • Source: Archive

More from Anticancer

More from Therapy Areas